Search research articles
Contact Us
Filters
Showing results (71-80 of 85) with videos related to
Page
of 9
Sort By:
International Journal of Clinical Oncology
|
October 18, 2015
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study)
Chu Matsuda, Michitaka Honda, Chihiro Tanaka, et al.
The Journal of Experimental Medicine
|
September 28, 2005
Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets
Yohichi Yasunami, Satoshi Kojo, Hiroshi Kitamura, et al.
Oncology Letters
|
March 31, 2017
Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)
Masanori Kotake, Toru Aoyama, Yoshinori Munemoto, et al.
International Journal of Cancer
|
June 20, 2022
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA
Jun Watanabe, Hiromichi Maeda, Takeshi Nagasaka, et al.
Asian Journal of Endoscopic Surgery
|
December 2, 2025
First Report of Single-Surgeon Single-Incision Laparoscopic Percutaneous Extraperitoneal Closure Using the Senhance Robotic System as Camera Holder for Pediatric Inguinal Hernia
Daiki Kato, Takahisa Tainaka, Chiyoe Shirota, et al.
Medical Oncology (Northwood, London, England)
|
April 26, 2019
Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
Naoki Nagata, Hiromichi Maeda, Keiichiro Ishibashi, et al.
Journal of Cancer
|
May 29, 2018
The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C)
Kazuhiro Nishikawa, Toru Aoyama, Mari S Oba, et al.
Cancer Chemotherapy and Pharmacology
|
September 23, 2020
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy
Masahito Kotaka, Yoji Saito, Takeshi Kato, et al.
Cancer Science
|
September 17, 2013
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan
Shoichi Hazama, Hideyuki Mishima, Ryouichi Tsunedomi, et al.
Biochemical and Biophysical Research Communications
|
October 12, 2004
Analyses to clarify rich fractions in hepatic progenitor cells from human umbilical cord blood and cell fusion
Yoshitada Tanabe, Fumihito Tajima, Yuki Nakamura, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 85) with videos related to
Sort By:
Page
of 9
International Journal of Clinical Oncology
|
October 18, 2015
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study)
Chu Matsuda, Michitaka Honda, Chihiro Tanaka, et al.
The Journal of Experimental Medicine
|
September 28, 2005
Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets
Yohichi Yasunami, Satoshi Kojo, Hiroshi Kitamura, et al.
Oncology Letters
|
March 31, 2017
Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)
Masanori Kotake, Toru Aoyama, Yoshinori Munemoto, et al.
International Journal of Cancer
|
June 20, 2022
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA
Jun Watanabe, Hiromichi Maeda, Takeshi Nagasaka, et al.
Asian Journal of Endoscopic Surgery
|
December 2, 2025
First Report of Single-Surgeon Single-Incision Laparoscopic Percutaneous Extraperitoneal Closure Using the Senhance Robotic System as Camera Holder for Pediatric Inguinal Hernia
Daiki Kato, Takahisa Tainaka, Chiyoe Shirota, et al.
Medical Oncology (Northwood, London, England)
|
April 26, 2019
Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
Naoki Nagata, Hiromichi Maeda, Keiichiro Ishibashi, et al.
Journal of Cancer
|
May 29, 2018
The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C)
Kazuhiro Nishikawa, Toru Aoyama, Mari S Oba, et al.
Cancer Chemotherapy and Pharmacology
|
September 23, 2020
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy
Masahito Kotaka, Yoji Saito, Takeshi Kato, et al.
Cancer Science
|
September 17, 2013
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan
Shoichi Hazama, Hideyuki Mishima, Ryouichi Tsunedomi, et al.
Biochemical and Biophysical Research Communications
|
October 12, 2004
Analyses to clarify rich fractions in hepatic progenitor cells from human umbilical cord blood and cell fusion
Yoshitada Tanabe, Fumihito Tajima, Yuki Nakamura, et al.
Page
of 9